Evaxion A/S (EVAX) Expected to Post Quarterly Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX – Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $0.30 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 8:30 AM ET.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $2.91 on Thursday. The company has a market capitalization of $26.25 million, a price-to-earnings ratio of -2.40 and a beta of 0.60. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.06 and a current ratio of 5.06. The company has a 50-day simple moving average of $3.14 and a 200 day simple moving average of $3.44. Evaxion A/S has a 52 week low of $2.67 and a 52 week high of $6.92.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.25.

Read Our Latest Stock Report on Evaxion A/S

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to develop novel immunotherapies and vaccines. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease-specific targets and support the development of treatments tailored to individual patients or pathogens. The company’s research and development activities focus primarily on personalized cancer vaccines and vaccines for infectious diseases. Evaxion’s pipeline has included programs intended to stimulate the immune system to recognize and attack cancer cells, as well as vaccine candidates targeting bacterial and viral infections.

Read More

Earnings History for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.